Medication and memory: Interactions among the elderly;Médicaments et mémoire: Des interactions à connaître chez le sujet âgé

Presse Medicale

Volumn 35, Issue 1 II, 2006, Pages 91-96

  Caer Frouard, Morgane ^a,b   Weill Engerer, Sébastien ^a   Piette, François ^a  

^a HÔPITAL ROTHSCHILD   (France)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; LITHIUM; METOCLOPRAMIDE; MIDAZOLAM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OXAZEPAM; PHENOTHIAZINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TRAMADOL; TRIHEXYPHENIDYL; TROPATEPINE; UNINDEXED DRUG; VALPROIC ACID; VERALIPRIDE; CORTICOSTEROID; DRUG; PSYCHOTROPIC AGENT;

AGED; AMNESIA; ANTEROGRADE AMNESIA; ATTENTION DEFICIT DISORDER; CENTRAL NERVOUS SYSTEM; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DRUG INDUCED DISEASE; DRUG SAFETY; ELDERLY CARE; HUMAN; MEMORY; MEMORY DISORDER; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; URINE RETENTION; AGE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG INTERACTION; IATROGENIC DISEASE; MENTAL DISEASE; SHORT TERM MEMORY;

ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; ANALGESICS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; DRUG INTERACTIONS; HUMANS; IATROGENIC DISEASE; LITHIUM; MEMORY; MEMORY DISORDERS; MEMORY, SHORT-TERM; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PHARMACEUTICAL PREPARATIONS; PSYCHOTROPIC DRUGS; RISK ASSESSMENT;

EID: 33644851595     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74529-8     Document Type: Article

References (49)

1. Baddeley AD. Working memory. Oxford: Oxford University Press; 1986.
2. Roy-Byrne PP, Uhde TW, Holcomb H, Thompson K, King AK, Weingartner H. Effects of diazepam on cognitive processes in normal subjects. Psychopharmacology. 1987; 91: 30-3.
3. Curran HV, Birch B. Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepines antagonist, flumazenil. Psychopharmacology. 1991; 103: 519-23.
4. Lister RG, File SE. The nature of lorazepam-induced amnesia. Psychopharmacology. 1984; 83: 183-7.
5. Preston GC, Broks P, Traub M, Ward C, Poppleton P, Stagl SM. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology. 1988; 95: 208-15.
6. Mintzer MZ, Griffiths RR. Lorazepam and scopolamine: a single dose comparison of effects on human memory and attentional processes. Exp Clin Psychopharmacology. 2003; 11: 56-72.
7. Kohnen R, Lienert GA. Defining tranquilizers operationally by non-addictive effect in experimental stress situations. Psychopharmacology. 1980; 68: 291-4.
8. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol. 1993; 44: 529-33.
9. Pomara N, Stanley B, Block R, Berchou RC, Stanley M, Greenblatt DJ et al. Increased sensitivity to the elderly to the central depressant effects of diazepam. J Clin Psychiatry. 1985; 46: 185-7.
10. Pomara N, Willoughby L, Wesnes K, Grennblatt DJ, Sidtis JJ. Apolipoprotein E e4allele and lorazepam effects on memory inhigh-functioning older adults. Arch Gen Psychiatry. 2005; 62: 209-16.
11. Afssaps. Prévenir la iatrogénèse médicamenteuse chez le sujet âgé. Juin 2005 http://agmed.sante.gouv.fr/htm/10/iatro/iatro.pdf
12. Amado-Boccara I, Gougoulis N, Poirier-Littré MF, Galinowski A, Loo H. Incidence des antidépresseurs sur les fonctions cognitives. L'Encéphale. 1994; 65-77.
13. Mattila MJ, Liljequist R, Seppala T. Effects of amitriptyline and mianserin psychomotor skills on memory in man. Br J Clin Pharmacol. 1978; 5: 535-55.
14. Schmitt JA, Kruizinga MJ, Riedel WJ. Non serotoninergic pharmacological profiles and associated cognitive effects of serotonin-reuptake inhibitors. J Psychopharmacol. 2001; 15: 173-9.
15. Siepmann M, Handel J, Mueck-Weymann M, Kirch W. The effects of moclobemide on autonomic and cognitive functions in healthy volunteers. Pharmacopsychiatry 2004; 37: 81-7.
16. Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG et al. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000; 157: 1949-54.
17. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled study. Br J Psychiatry. 1996; 168: 149-57.
18. Beuzen JN, Taylor N, Wesnes K, Wood A. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol. 1999; 13: 152-8.
19. Allain H, Tessier C, Bentue-Ferrer D, Tarral A, Le Breton S, Gandon M et al. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology. 2003; 165: 419-29.
20. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997; 314: 266-70.
21. Lee P, Gill S, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia: systematic review. BMJ. doi:10.1136/bmj.38125.465579.55
22. Afssaps. agmed.sante.gouv.fr/htm/10/filco-prs/040301.htm
23. Stip E, Dufresne J, Lussier I, Yathan L. A double blind, placebo controlled study of the effects of lithium on cognition in healthy subjects: mild and selective effects on learning. J Affect Disord. 2000; 60: 147-57.
24. Harmer CJ, Clark L, Grayson L, Goodwin GM. Sustained attention deficit in bipolar disorder is not a working memory impairment in disguise. Neuropsychologia. 2002; 40: 1586-90.
25. Honig A, Arts BM, Ponds RW, Riedel WJ. Lithium induced cognitive side effects in bipolar disorder: a qualitative analysis and implication for daily practice. Int Clin Psychopharmacol. 1999; 14: 167-71.
26. Lonergan ET, Luxenberg J. Valproate preparations for agitation in dementia. The Cochrane Database of Systematic reviews 2204, Issue 2. Art. No.: CD003945.pub2.
27. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998; 155: 54-61.
28. Meador KJ, Loring DW, Moore EE, Thompson WO, Nichols ME, Oberzan RE et al. Comparative cognitive effects of Phenobarbital, phenytoin, and valproate in healthy adults. Neurology. 1995; 45: 1494-9.
29. Thompson PJ, Baxendale SA, Duncan JS, Sander JWAS. Effects of topiramate on cognitive functions. J Neurol Neurosurg Psychiatry. 2000; 69: 636-41.
30. Aldenkamp AP, De Kron M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia. 2003; 44(suppl4): 21-9.
31. O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain. 2000; 85: 209-15.
32. Conley KM, Toledano AY, Apfelbaum JL, Zacny JP. Modulating effects of a cold water stimulus on opioid effects in volunteers. Psychopharmacology. 1997; 131: 313-20.
33. Hart RP, Wade JB, Martelli MF. Cognitive impairment in patients with chronic pain: the significance of stress. Curr Pain Headache Rep. 2003; 7: 116-26.
34. Chapman SL, Byas-Smith MG, Reed BA. Effects of intermediate- and long term use of opioids on cognition in patients with chronic pain. Clin J Pain. 2002; 18: S83-90.
35. Clemons M, Regnard C, Appleton T. Alertness, cognition and morphine in patients with advanced cancer. Cancer Tret Rev. 1996; 22: 451-68.
36. Veselis RA, Reinsel RA, Feshchenko VA, Wronski M. The comparative amnestic effects of midazolam, propofol, thiopental, and fentanyl at equisedative concentrations. Anesthesiology. 1997; 87: 749-64.
37. Zacny JP. A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exp Clin Psychopharmacol. 1995; 3: 432-66.
38. Ghoneim MM, Mewaldt SP. Studies on human memory: the interaction of diazepam, scopolamine and physostigmine. Psychopharmacology. 1977; 52: 1-6.
39. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia. 1988; 26: 685-700.
40. Katz IR, Greenberg WM, Barr GA, Garbarino C, Buckley P, Smith D. Screening for cognitive toxicity of anticholinergic drugs. J Clin Psychiatry. 1985; 46: 323-6.
41. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999; 15: 15-28.
42. Minzenberg MJ, Poole JH, Benton C, Vinogradow S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004; 161: 116-24.
43. Nishiyama K, Momose T, Sugishita M, Sakuta M. Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy. J Neurol Sci. 1995; 132: 189-92.
44. Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry. 1992; 149: 1393-4.
45. Nacher J, Pham K, Gil-Fernandez V, McEwen BS. Chronic restraint stress and chronic corticosterone treatment modulate differentially the expression of molecules related to structural plasticity in the adult rat piriform cortex. Science. 2004; 126: 503-9.
46. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effects on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996; 47: 1396-402.
47. Schmidt LA, Fox NA, Goldberg MC, Smith CC, Schulkin J. Effects of acute prednisone administration on memory, attention and emotion in healthy human adults. Psychoneuroendocrinology 1999; 24: 461-83.
48. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction and cortisol levels in patients with Cushing's Syndrome. Biol Psychiatry. 1992; 32: 756-65.
49. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology. 2000; 54: 588-99.